IDEAYA Biosciences, Inc. (IDYA) PT Increased as Wedbush Highlights Positive OptimUM-02 Trial Readout

We recently compiled a list of the Top 10 AI-Powered Biotech Stocks to Buy Right Now. IDEAYA Biosciences, Inc. is among the best biotech stocks to invest in.

TheFly reported on April 14 that Wedbush Securities increased its price target on IDYA from $52 to $58 while maintaining an Outperform rating. The update followed the company’s release of top-line results from its Phase 2/3 OptimUM-02 clinical trial. Management reported that safety outcomes remain consistent with earlier studies, with adverse events generally manageable. The firm also noted that additional detailed findings from the study are expected to be shared at a major medical conference in 2026, which could provide further clarity on the program’s clinical profile and future development potential.

Adding to the company’s operational momentum, on April 6, IDEAYA Biosciences, Inc. (NASDAQ:IDYA) reported that it has begun patient enrollment in a Phase 1 dose-escalation study of IDE574, a first-in-class oral small-molecule therapy designed to inhibit KAT6 and KAT7, two epigenetic targets involved in cancer cell survival.

IDEAYA Biosciences, Inc. (IDYA) PT Increased as Wedbush Highlights Positive OptimUM-02 Trial Readout

The early-stage trial will assess safety, pharmacokinetics, and preliminary anti-tumor activity as a monotherapy in patients with advanced solid tumors, including breast, prostate, colorectal, and lung cancers. The program is intended to evaluate a novel dual-mechanism approach aimed at overcoming resistance pathways in oncology and expanding treatment options in multiple high-need cancer indications through epigenetic modulation strategies.

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is an AI-driven precision oncology company focused on synthetic lethality-based cancer therapies. It uses machine learning and physics-based drug discovery to develop first-in-class targeted cancer treatments guided by molecular diagnostics.

While we acknowledge the risk and potential of IDYA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than IDYA and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 9 Most Undervalued Healthcare Stocks to Buy Now and 10 Most Undervalued Dow Stocks to Buy Now.

Disclosure: None. Follow Insider Monkey on Google News.